Thursday, November 18, 2021 Daily Archives

Ins & Outs: Filling gaps at Pfizer and the FDA

by

Pfizer’s chief financial officer Frank D’Amelio will retire from his position after 15 years at the firm, prompting an external search for his successor. Meanwhile, Joe Biden nominates Robert Califf for US FDA chief. Sit back, relax, and enjoy this week’s Ins &Outs. Pfizer announced D’Amelio’s planned departure from the company and stated he has agreed to stay on board in a consulting role while the firm externally search for a chief financial officer (CFO). Pfizer claim that during D’Amelio’s…

November 18, 2021

Novo Nordisk to add RNAi engine in $3.3bn Dicerna buy

by

The acquisition of development partner Dicerna Pharmaceuticals will accelerate Novo Nordisk’s position in the RNA interference (RNAi) space. In 2019, Novo Nordisk paid $175 million upfront to collaborate with Dicerna in the discovery and development of RNAi therapies for liver-related cardiometabolic diseases using Dicerna’s proprietary GalXC RNAi platform technology. Two years on, and the Danish drugmaker has entered an agreement to buy the partner outright, offering $38.25 per share and valuing the firm at around $3.3 billion. “The acquisition of…

November 18, 2021

Increasing productivity in cell and gene therapy bioprocessing with fast and reliable immunoassays

by

Cell and gene therapy manufacturers need to ensure the safe delivery of their products and rely on fast and reliable immunoassay platforms to do so. This white paper gives an overview of the viral vector landscape and the requirements for immunoassays in viral vector bioprocessing analytical workflow. It also shares case studies from viral vector labs that are using the Gyrolab technology to deliver fast and reliable results. Increasing productivity in cell and gene therapy bioprocessing with fast and reliable…

November 18, 2021